Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs). Three large electronic databases were system...

Full description

Bibliographic Details
Main Authors: Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, Alessandro Csermely, Amedeo Lonardo, Giovanni Targher
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Metabolites
Subjects:
GLP-1 receptor agonists
exenatide
liraglutide
semaglutide
dulaglutide
nonalcoholic fatty liver disease
Online Access:https://www.mdpi.com/2218-1989/11/2/73

Internet

https://www.mdpi.com/2218-1989/11/2/73

Similar Items